Insights from
UBC's Expert Voices

Artificial intelligence is transforming pharmacovigilance—but human expertise remains essential. As AI systems evolve to support drug safety monitoring, ensuring human oversight is key to managing risk, improving outcomes, and maintaining trust. At UBC, we’re blending AI innovation with deep PV knowledge, empowering our teams through AI awareness training and shaping a safer future for patients. Discover how AI and humans can work together to advance pharmacovigilance.

UBC’s approach to real-world data tokenization and linkage enhances study results with longitudinal observation of various participant health outcomes during the pre-and post-trial period.

Linking longitudinal real-world data (RWD) to clinical study data offers deeper insights for drug developers. Contextualize study outcomes, extend data collection after the study ends, close the efficacy-effectiveness gap, and identify post-market patterns.

UBC Pharmacovigilance experts, Dobrochna Dolicka, Christopher Henry, Alix Garcia and Irene Navarro presented at DIA Europe 2025 on how AI can be used to streamline pharmacovigilance activities and how harmonization of guidelines can be enhanced in order to define a specific framework for gene therapy.

Psychedelic-assisted therapies are starting to emerge with potential as treatments for mental health conditions. Explore the evidence behind an increased interest in this use of substances such as psilocybin, MDMA, LSD, and DMT, and the future of research in this area.

Adherence is critical to ensuring patients receive full therapeutic benefit and effectively manage their disease, particularly for complex treatments such as injectables or infusions. Explore strategies to support patients and improve adherence in the blog.

Dive deep on a number of developments occurred during 2024 that will drive considerations in risk management and REMS for 2025 and beyond.

This article explores strategies to enhance Patient Service Programs (PSPs) awareness through digital engagement and provider collaboration.

Learn about the FDA's new guidance, the challenges of standardization, and how UBC is driving innovation in REMS implementation using modern APIs from UBC's VP of Data Intelligence and Program Analytics, Jim Shamp.